HuMax-CD74-ADC

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameHuMax-CD74-ADC

Drug Alias NameHuMax-CD74

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionHLA-DR antigens-associated invariant chain inhibitors

TargetsHLA-DR antigens-associated invariant chain

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmark

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGenmab A/S

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenmab A/S

Active IndicationsN/A

Inactive IndicationsSolid tumoursHematologic Neoplasms

Other Information

ATC CodeN/A